"Fraunhofer vs. Corona": iCAIR® project enhanced to include coronavirus SARS-CoV-2
In the iCAIR® project, Fraunhofer ITEM is collaborating with partners – Griffith University's Institute for Glycomics (IfG) in Australia, the Institute for Clinical Biochemistry at the Hannover Medical School (MHH), and the Helmholtz Centre for Infection Research (HZI) – to develop new, urgently needed agents against infectious diseases that are gaining ground worldwide. In their development of novel anti-infectives, they go all the way from the identification of potentially beneficial substances to the preclinical proof of concept. In view of the corona pandemic, the project has been enhanced to include the search for an effective drug against the coronavirus SARS-CoV-2.
Dr. Christoph Neubert, manager of a Fraunhofer-program, interviewed iCAIR® coordinator, Prof. Armin Braun of Fraunhofer ITEM in Hannover and project manager Prof. Mark von Itzstein of Griffith University in Australia, about their research activities and how they are facing the challenge of finding an effective drug.